Thurm 1991.

Methods	Randomised double‐blind placebo controlled study. Withdrawals and drop‐outs were reported
Participants	14 patients were recruited. All patients had pulmonary hypertension, due to systemic sclerosis. 13 completed the study. 6 patients in the iloprost group and 7 in the placebo group. Age range: 35‐72 (8 whites and 5 blacks). Mean age 55 in Ilosprost group and 45 in placebo. Gender: 5F and 1M in iloprost group and in placebo group 5F and 2M.
Interventions	IV iloprost or placebo, dose range (0.5 to 2ng per kg, per min). Trial duration 3 days. All other therapies were stopped.
Outcomes	Lung function and changes in sitting and supine positions.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomisation was not specified.
Allocation concealment?	Unclear risk	Allocation concealment was not specified.

PAH: pulmonary arterial hypertension; PLA: placebo; RAP: right arterial pressure; PAP: pulmonary arterial pressure; PCWPm: mean capillary wedge pressure; CI: Cardiac index; PVRI: pulmonary vascular resistance index: VO2: oxygen consumption; ERAs: endothelin receptor antagonists. BER: beraprost; TREP: treprostinil; MV Sat: mixed venous saturation